High-Density Genetic Map Construction and Identification of QTLs Controlling Oleic and Linoleic Acid in Peanut using SLAF-seq and SSRs.

The cultivated peanut, A. hypogaea L., is an important oil and food crop globally.High-density genetic linkage mapping is a valuable and effective method for exploring complex quantitative traits. In this context, a recombinant inbred line (RIL) of 146 lines was developed by crossing Huayu28 and P76. We developed 433,679 high-quality SLAFs, of which 29,075 were polymorphic. 4,817 SLAFs were encoded and grouped into different segregation patterns. A high-resolution genetic map containing 2,334 markers (68 SSRs and 2,266 SNPs) on 20 linkage groups (LGs) spanning 2586.37 cM was constructed for peanut. The average distance between adjacent markers was 2.25 cM. Based on phenotyping in seven environments, QTLs for oleic acid (C18:1), linoleic acid (C18:2) and the ratio of oleic acid to linoleic acid (O/L) were identified and positioned on linkage groups A03, A04, A09, B09 and B10. Marker2575339 and Marker2379598 in B09 were associated with C18:1, C18:2 and O/L in seven environments, Marker4391589 and Marker4463600 in A09 were associated with C18:1, C18:2 and O/L in six environments. This map exhibits high resolution and accuracy, which will facilitate QTL discovery for essential agronomic traits in peanut.

A novel HLA-A*31 allele, A*31:126N, was identified by sequence-based typing.

A novel allele A*31:126N was identified in a Chinese individual by sequence-based typing method.

The novel allele, HLA-A*11:264, was identified in a Chinese individual by sequence-based typing.

The novel allele, A*11:264, was identified in a Chinese individual by sequence-based typing.

A novel HLA-A*02 allele, A*02:692, was identified by sequencing-based typing.

One nucleotide replacement at nucleotide 811 of HLA-A*02:01:01:01 results in a new allele, HLA-A*02:692.

[Efficacy of Weitan Waifu patch on the postsurgical gastroparesis syndrome of gastrointestinal cancer: a multi-center trial].

Objective: To investigate the safety and efficacy of the Weitan Waifu patch on the postsurgical gastroparesis syndrome (PGS) of gastrointestinal cancer. Methods: The multi-center, double-blind, randomized controlled trial was conducted with superiority design. Patients with PGS of gastrointestinal cancer diagnosed in 4 AAA hospitals and the abdominal symptom manifested as cold syndrome by Chinese local syndrome differentiation were recruited. These patients were randomly divided into two groups according to 1∶1 proportion. Placebo or Weitan Waifu patch was applied in control group or intervention group, respectively, based on the basic treatments, including nutrition support, gastrointestinal decompression, promoting gastric dynamics medicine.Two acupuncture points (Zhongwan and Shenque) were stuck with placebo in control group or patch in treatment group. The intervention course was 14 days or reached the effective standard. Results: From July 15, 2013 to Jun 3, 2015, 128 participants were recruited and 120 eligible cases were included in the full analysis set (FAS), and 60 cases in each group. 88 cases were included in the per-protocol set (PPS), including 45 cases in the treatment group and 43 cases in the control group. In the FAS, the clinical effective rate in the treatment group was 68.3%, significantly superior than 41.7% of the control group (P=0.003). The medium time of effective therapy in the treatment group was 8 days, significantly shorter than 10 days in the control group (P=0.017). In the FAS, 3 adverse events occurred in the treatment group, including mild to moderate decrustation, pruritus and nausea. The incidence rate of adverse events was 5.0% (3/60) and these symptoms were spontaneously remitted after drug withdrawal. No severe adverse events were observed in the control group. There was no significant difference between these two groups (P=0.244). Conclusion: Weitan Waifu patch is a safely and effectively therapeutic method for patients with PGS (cold syndrome) of gastroenterological cancer. Trial registration: International Standard Randomized Controlled Trial Number Register, ISRCTN18291857.

A novel HLA-A*24 allele, A*24:02:61, confirmed in a Chinese individual.

A novel HLA-A*24 allele, A*24:02:61, confirmed in a Chinese individual.

A novel HLA-A*24 allele, A*24:337, was identified by sequencing-based typing.

A novel allele A*24:337 was identified in a Chinese individual by sequence-based typing.

A novel HLA-DRB1*04 allele, DRB1*04:01:17, was identified by sequencing-based typing.

A novel allele DRB1*04:01:17 was identified in a Chinese individual by sequence-based typing method.

A novel HLA-A*02 allele, A*02:436, was identified by sequencing-based typing.

A novel allele A*02:436 was identified in a Chinese individual by sequence-based typing method.

A new HLA-A allele, HLA-A* 02:01:119, identified in a Chinese individual.

The new allele A*02:01:119 was initially identified in a Chinese individual by sequence-based typing.

A novel HLA-B*13 allele, B*13:68, was identified by sequencing-based typing.

A novel allele B*13:68 was identified in a Chinese individual by sequence-based typing method.

A novel HLA-A*11 allele, A*11:97, was identified by sequencing-based typing.

A novel allele A*11:97 was identified in a Chinese individual by sequence-based typing method.

Identification of a novel HLA-B*46 allele, B*46:01:07, in a Chinese individual.

The novel allele B*46:01:07 was identified in a Chinese individual by sequence-based typing.

A novel HLA-B44 allele, B*44:127, was identified by sequencing-based typing.

In this report we describe a novel allele B*44:127, which was identified in a Chinese voluntary bone marrow donor by sequence-based typing. HLA-B*44:127 showed one nucleotide difference from G to A with HLA-B*44:02:01 at nucleotide 320.

Identification of a novel HLA-B*40 allele, B*40:162, in a Chinese individual.

The allele was identified in a Chinese individual by sequence-based typing. HLA-B*40:162 differs from B*40: 06:01 by a single nucleotide at position 272 C→T in exon 2.

Influence of angiostatin and thalidomide on lymphangiogenesis.

Malignant cancers commonly invade locally followed by spread through venous or lymphatic channels or both to distant sites. Hemangiogenesis and its relation to tumor growth and metastasis have been extensively studied. However, the role played by lymphangiogenesis in growth and metastasis of cancer has been largely neglected until just recently. Inhibition of lymphangiogenesis, as compared to inhibition of hemangiogenesis, may provide new insights into the mechanisms of cancer metastasis. The current study was designed to examine the in vitro effect of two commonly used inhibitors of hemangiogenesis, angiostatin and thalidomide, on the growth and proliferation of lymphatic endothelial cells isolated from pig thoracic ducts. We first isolated and characterized the lymphatic endothelial (LE) cells using specific markers for VEGFR3 and LYVE-1. The experimental results showed that treatment of the LE cells with these two drugs resulted in a decrease in the rate of cell proliferation in a dose-dependent manner as assessed by MTT assays. Cell migration rate was assessed by the speed of cell migration from the scrape-wound margin, and the results showed that migration of LE cells was also significantly inhibited in a dose-dependent fashion compared to controls. Treatment with angiostatin and thalidomide both resulted in an increase in apoptosis of LE cells as assessed by Hoechst staining and flow cytometry. We conclude that both angiostatin and thalidomide are able to inhibit LE cell growth in a dose-dependent manner and that the inhibition may be through induction of apoptosis.